Aug 24, 2026 · 2h 6m
Harvard geneticist David Sinclair projects human trials for cellular age reversal
“Age Reversal Is Coming.” Inside The First Human Trials - Dr David Sinclair - #1141
The transition of cellular reprogramming from laboratory theory to human trials could fundamentally redefine how medicine treats age-related diseases.
- 1Cellular reprogramming therapies have successfully restored vision in animal models by resetting genetic data without altering cell identity.
- 2Effective longevity protocols prioritize biological stress through structured fasting windows and targeted temperature exposure.
- 3Artificial intelligence is rapidly accelerating the discovery of chemical cocktails designed to mimic genetic age reversal.
Don't miss
David Sinclair explains how his lab's gene therapy successfully reversed blindness in mice, marking a major milestone toward human trials.
The brief
Harvard geneticist David Sinclair returns to discuss the accelerating timeline of cellular age reversal, moving from successful animal trials to the brink of human gene therapy.
Rather than just slowing decline, new research focus on rebooting the cell's genetic software to restore youthful function without erasing cellular identity.
Beyond future clinical therapies, practical longevity relies on immediate metabolic stressors like fasting, cold exposure, and managing the MTOR pathway.
As AI accelerates drug discovery, the landscape is shifting from complex biohacking routines toward targeted chemical cocktails and accessible daily protocols.
Featuring
David SinclairMentioned
Gene therapy
Cellular aging
FastingListen to the full episode and explore every guest, topic, and moment on PodLume.